Targeting hypoxia-induced factor 1α (HIF-1α), a key regulator of the cellular response to hypoxia, and activating the mTORC1 pathway may hold promise in overcoming drug resistance in T-ALL within the hypoxic BM TME139. Here, HIF1A is linked to acute lymphoblastic leukemia.